Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, bre... Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviros advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. 더 보기
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview...
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, Chief Scientific Officer...
ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.23 | -12.6373626374 | 1.82 | 1.85 | 1.4618 | 281491 | 1.57837578 | CS |
4 | -0.11 | -6.47058823529 | 1.7 | 3.25 | 0.851 | 7602974 | 2.08735884 | CS |
12 | 0.18 | 12.7659574468 | 1.41 | 3.25 | 0.851 | 2553276 | 2.08532204 | CS |
26 | -2.41 | -60.25 | 4 | 4 | 0.851 | 1609329 | 2.07864912 | CS |
52 | -2.41 | -60.25 | 4 | 4 | 0.851 | 1609329 | 2.07864912 | CS |
156 | -2.41 | -60.25 | 4 | 4 | 0.851 | 1609329 | 2.07864912 | CS |
260 | -2.41 | -60.25 | 4 | 4 | 0.851 | 1609329 | 2.07864912 | CS |
기호 | 가격 | 볼륨 |
---|---|---|
SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 25.06 (-23.25%) | 196.04M |
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3.78 (33.81%) | 130.6M |
SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 22.22 (22.83%) | 113.36M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5.89 (4.25%) | 103.9M |
MJUSAmplify US Alternative Harvest ETF | US$ 0.7584 (-2.77%) | 76.69M |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관